Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arrhythmia monitors should be Class II devices subject to special controls -- Zymed petition.

This article was originally published in The Gray Sheet

Executive Summary

ARRHYTHMIA MONITOR DOWNCLASSIFICATION TO CLASS II WITH SPECIAL CONTROLS is called for by Zymed Medical Instrumentation in a July 30 petition to FDA. The Camarillo, California-based company bases its argument on the fact that the "algorithm core" used in its Central Station telemetry arrhythmia monitoring system is identical to that employed in other Zymed arrhythmia detection systems used to retrospectively review electrocardiograph data, which are regulated as Class II devices.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel